Imugene Limited (IUGNF)
USD 0.03
(4.0%)
USD 0.03
(4.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -135.09 Million AUD | -262.52% |
| 2023 | -37.26 Million AUD | -31.06% |
| 2022 | -37.45 Million AUD | -105.34% |
| 2021 | -18.24 Million AUD | -75.04% |
| 2020 | -10.42 Million AUD | -35.23% |
| 2019 | -7.7 Million AUD | -33.36% |
| 2018 | -5.77 Million AUD | -56.8% |
| 2017 | -3.68 Million AUD | 13.66% |
| 2016 | -4.26 Million AUD | -63.48% |
| 2015 | -194.89 Thousand AUD | -834.42% |
| 2014 | -796.81 Thousand AUD | 120.44% |
| 2013 | -1.73 Million AUD | -258.96% |
| 2012 | -995.32 Thousand AUD | 60.37% |
| 2011 | 682.09 Thousand AUD | 138.32% |
| 2010 | -1.78 Million AUD | 26.27% |
| 2009 | -2.41 Million AUD | -8.93% |
| 2008 | -2.21 Million AUD | 4.54% |
| 2007 | -2.69 Million AUD | 17.24% |
| 2006 | -2.8 Million AUD | -29.57% |
| 2005 | -2.16 Million AUD | -33.89% |
| 2004 | -1.61 Million AUD | 29.57% |
| 2003 | -2.29 Million AUD | -198.22% |
| 2002 | -770 Thousand AUD | 77.49% |
| 2001 | -3.42 Million AUD | 22.27% |
| 2000 | -4.4 Million AUD | 10.24% |
| 1999 | -4.9 Million AUD | -8.52% |
| 1998 | -4.51 Million AUD | -113.72% |
| 1997 | -2.11 Million AUD | 49.02% |
| 1996 | -4.14 Million AUD | -174.09% |
| 1995 | -1.51 Million AUD | -73.71% |
| 1994 | -871 Thousand AUD | -185.57% |
| 1993 | -305 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -67.55 Million AUD | 0.0% |
| 2024 Q1 | -34.57 Million AUD | -237.28% |
| 2024 Q2 | -34.57 Million AUD | 0.0% |
| 2024 FY | - AUD | -175.19% |
| 2023 Q2 | -8.38 Million AUD | 0.0% |
| 2023 Q3 | -10.25 Million AUD | -22.32% |
| 2023 FY | - AUD | -31.06% |
| 2023 Q4 | -10.25 Million AUD | 0.0% |
| 2023 Q1 | -8.38 Million AUD | 21.49% |
| 2022 Q1 | -7.04 Million AUD | -23.28% |
| 2022 FY | - AUD | -105.34% |
| 2022 Q4 | -10.67 Million AUD | 0.0% |
| 2022 Q3 | -10.67 Million AUD | -51.45% |
| 2022 Q2 | -7.04 Million AUD | 0.0% |
| 2021 Q2 | -10.14 Million AUD | -235.7% |
| 2021 Q1 | -3.02 Million AUD | -3.25% |
| 2021 FY | - AUD | -75.04% |
| 2021 Q4 | -5.71 Million AUD | 7.52% |
| 2021 Q3 | -6.18 Million AUD | 39.03% |
| 2020 Q4 | -2.92 Million AUD | 0.08% |
| 2020 FY | - AUD | -35.23% |
| 2020 Q3 | -2.92 Million AUD | -20.2% |
| 2020 Q2 | -2.43 Million AUD | 0.0% |
| 2020 Q1 | -2.43 Million AUD | 65.19% |
| 2019 Q1 | -1.85 Million AUD | -61.7% |
| 2019 FY | - AUD | -33.36% |
| 2019 Q4 | -6.99 Million AUD | -209.92% |
| 2019 Q3 | -2.25 Million AUD | -21.99% |
| 2019 Q2 | -1.85 Million AUD | 0.0% |
| 2018 Q1 | -822.47 Thousand AUD | -58.77% |
| 2018 Q2 | -822.47 Thousand AUD | -0.0% |
| 2018 Q3 | -1.14 Million AUD | -39.18% |
| 2018 Q4 | -1.14 Million AUD | 0.0% |
| 2018 FY | - AUD | -56.8% |
| 2017 FY | - AUD | 13.66% |
| 2017 Q4 | -518.04 Thousand AUD | 0.0% |
| 2017 Q3 | -518.04 Thousand AUD | 30.14% |
| 2017 Q2 | -741.51 Thousand AUD | -0.0% |
| 2017 Q1 | -741.51 Thousand AUD | 8.97% |
| 2016 Q1 | -537.08 Thousand AUD | -605.21% |
| 2016 Q4 | -814.6 Thousand AUD | 0.0% |
| 2016 Q3 | -814.6 Thousand AUD | -51.67% |
| 2016 Q2 | -537.08 Thousand AUD | 0.0% |
| 2016 FY | - AUD | -63.48% |
| 2015 Q4 | -76.16 Thousand AUD | 0.0% |
| 2015 FY | - AUD | -834.42% |
| 2015 Q1 | -21.28 Thousand AUD | 83.77% |
| 2015 Q2 | -21.28 Thousand AUD | 0.0% |
| 2015 Q3 | -76.16 Thousand AUD | -257.79% |
| 2014 Q3 | -131.13 Thousand AUD | 50.94% |
| 2014 Q4 | -131.13 Thousand AUD | 0.0% |
| 2014 Q2 | -267.27 Thousand AUD | 0.0% |
| 2014 Q1 | -267.27 Thousand AUD | -65.73% |
| 2014 FY | - AUD | 120.44% |
| 2013 FY | - AUD | -258.96% |
| 2013 Q3 | -118.41 Thousand AUD | 0.0% |
| 2013 Q4 | -161.27 Thousand AUD | -36.19% |
| 2012 FY | - AUD | 60.37% |
| 2011 FY | - AUD | 138.32% |
| 2010 FY | - AUD | 26.27% |
| 2009 FY | - AUD | -8.93% |
| 2008 FY | - AUD | 4.54% |
| 2007 FY | - AUD | 17.24% |
| 2006 FY | - AUD | -29.57% |
| 2005 FY | - AUD | -33.89% |
| 2004 FY | - AUD | 29.57% |
| 2003 FY | - AUD | -198.22% |
| 2002 FY | - AUD | 77.49% |
| 2001 FY | - AUD | 22.27% |
| 2000 FY | - AUD | 10.24% |
| 1999 FY | - AUD | -8.52% |
| 1998 FY | - AUD | -113.72% |
| 1997 FY | - AUD | 49.02% |
| 1996 FY | - AUD | -174.09% |
| 1995 FY | - AUD | -73.71% |
| 1994 FY | - AUD | -185.57% |
| 1993 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -9536.901% |
| CSL Limited | 4.78 Billion USD | 102.821% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -90.172% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -2178.511% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -56387.916% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -677.725% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 243.655% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -8694.697% |
| Mesoblast Limited | -62.38 Million USD | -116.527% |
| Marizyme, Inc. | -34.28 Million USD | -294.064% |
| Genus plc | 73.7 Million USD | 283.298% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1943.266% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -3708.597% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -1440.023% |
| ContraFect Corporation | -64.99 Million USD | -107.835% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -2884.645% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | -280.287% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -5713.31% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -25976.999% |
| Accustem Sciences Inc. | -3.74 Million USD | -3505.866% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -180.115% |
| EV Biologics, Inc. | -1.26 Million USD | -10561.151% |
| Q BioMed Inc. | -617.62 Thousand USD | -21772.527% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 3881.939% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -5813.395% |
| Biomind Labs Inc. | -1.03 Million USD | -12957.946% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1786.408% |
| Skye Bioscience, Inc. | -13.54 Million USD | -897.161% |
| SQZ Biotechnologies Company | -64.14 Million USD | -110.615% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -540263.4% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -3377.851% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -5008.471% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -751.248% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -21261.412% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 1467.732% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -8982.275% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -5299.397% |
| GB Sciences, Inc. | -1.41 Million USD | -9414.211% |
| Alpha Cognition Inc. | -9.7 Million USD | -1291.885% |
| argenx SE | -216.02 Million USD | 37.465% |
| HST Global, Inc. | -5303.00 USD | -2547342.014% |
| Halberd Corporation | -74.27 Thousand USD | -181769.506% |
| Enzolytics Inc. | -2.12 Million USD | -6266.117% |
| Resverlogix Corp. | -11.74 Million USD | -1050.493% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -4310.387% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -144.115% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -240.821% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 11200.316% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -4570.665% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1625.795% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 2009184.622% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -8912.63% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 35758.701% |
| AVAX Technologies, Inc. | -6.11 Million USD | -2110.024% |
| ONE Bio Corp. | 13.61 Million USD | 1092.363% |
| Zenith Capital Corp. | -8.6 Million USD | -1469.729% |
| Genscript Biotech Corporation | -248.71 Million USD | 45.685% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -775348.31% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -5421.889% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -76645.542% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -6932.645% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -6467.372% |
| Agentix Corp. | -1.37 Million USD | -9748.023% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -5047.532% |
| Helix BioMedix, Inc. | -1.04 Million USD | -12811.144% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -7619.482% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1688.419% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -74499.559% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 32866.534% |
| Cell Source, Inc. | -4.27 Million USD | -3061.85% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -36687.343% |
| Regen BioPharma, Inc. | 1.46 Million USD | 9315.205% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -14318.165% |
| NovAccess Global Inc. | -1.03 Million USD | -12954.817% |
| Affymax, Inc. | -14.29 Million USD | -845.022% |
| Itoco Inc. | -1.86 Million USD | -7127.994% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -35485.809% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -12004.915% |
| CytoDyn Inc. | -18.02 Million USD | -649.298% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -170838.326% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1104576.18% |
| Qrons Inc. | -40.08 Thousand USD | -336944.61% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -27714.9% |
| SYBLEU INC | -141.57 Thousand USD | -95322.685% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 25712.893% |
| Rebus Holdings, Inc. | -951 Thousand USD | -14105.137% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -12620.299% |
| Mobile Lads Corp. | -2.24 Million USD | -5927.723% |
| International Stem Cell Corporation | 202 Thousand USD | 66976.658% |
| Bioxytran, Inc. | -3.82 Million USD | -3436.274% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -256531.554% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -5387.189% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -276.623% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -300101.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -4833.924% |
| Neutra Corp. | -181.24 Thousand USD | -74434.116% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -570.127% |
| PureTech Health plc | -11.62 Million USD | -1061.872% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -570.173% |
| IXICO plc | -707 Thousand USD | -19007.617% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1657.851% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -179.425% |
| CSL Limited | 4.73 Billion USD | 102.854% |
| Cellectis S.A. | -92.63 Million USD | -45.83% |